In Silico Evaluation Of Eugenol As A Potential Antifungal Agent: Targeting Beta-Glucocerebrosidase And Cyp51
DOI:
https://doi.org/10.52783/jns.v14.3106Keywords:
Eugenol, Antifungal activity, Molecular docking, Beta-glucocerebrosidase, Demethylase, Fungal transcription factor Upc2Abstract
Fungal infections pose a significant health risk, with a growing concern for drug-resistant strains. This study investigates the potential of Eugenol (PubChem ID: 3314), a natural compound, as an antifungal agent through molecular docking analysis. The research targets three key fungal virulence proteins: beta-glucocerebrosidase (9FA3), Demethylase (6UEZ), and Upc2 (7VPU), utilizing AutoDock 1.5.7 to evaluate binding affinities and molecular interactions. Eugenol exhibited the strongest binding affinity for beta-glucocerebrosidase (−5.76 kcal/mol, 59.89 µM), where it formed crucial hydrogen bonds with residues SER-77 and TYR-79, indicating a strong potential for enzymatic inhibition. For Demethylase, Eugenol’s binding affinity was −5.53 kcal/mol (88.85 µM), suggesting moderate potential in disrupting fungal cell metabolism. In the case of Upc2, Eugenol displayed a slightly lower affinity (−4.99 kcal/mol, 219.20 µM), yet still indicated possible interactions that could interfere with fungal sterol regulation. These findings highlight Eugenol’s promising multi-target antifungal activity, particularly against key fungal enzymes involved in virulence and metabolic processes. The results suggest that Eugenol may be a viable candidate for further experimental investigation as a natural antifungal agent. Future in vitro and in vivo studies are necessary to confirm these computational predictions and explore the broader therapeutic potential of Eugenol in treating fungal infections.
Downloads
Metrics
References
Alshammari, F. (2020). "Antifungal resistance: An emerging global health threat." Journal of Infection and Public Health, 13(2), 226-233.
Pfaller, M. A., & Diekema, D. J. (2010). "Epidemiology of invasive mycoses in North America." Clinical Infectious Diseases, 51(6), 631-633.
Rajendran, R., & Sherry, L. (2017). "Biofilms in fungal infections: Pathogenesis, monitoring, and treatment." Frontiers in Microbiology, 8, 2081.
Sugui, J. A., & Kwon-Chung, K. J. (2014). "Immune evasion strategies of fungal pathogens." Frontiers in Microbiology, 5, 362.
Latgé, J. P. (2010). "The cell wall: A carbohydrate armor for the fungal cell." Molecular Microbiology, 75(2), 245-254.
White, T. C., & Berman, J. (2012). "The antifungal drug resistance of Candida albicans." Future Microbiology, 7(5), 533-544.
Dufresne, M., & Giguère, M. (2019). "CYP51 inhibitors in antifungal drug discovery." Journal of Medicinal Chemistry, 62(5), 2339-2357.
Sanguinetti, M., & Posteraro, B. (2015). "Emerging resistance in Candida species." Clinical Infectious Diseases, 60(Suppl 3), S14-S23.
Hamid, M. A., & Khan, M. I. (2013). "Eugenol: A potential antifungal agent." International Journal of Phytomedicine, 5(3), 180-185.
Wang, Q., et al. (2020). "The antifungal activity of Eugenol against Candida species: A review." Antibiotics, 9(9), 606.
Piddock, L. J. V., & Zong, Z. (2012). "Antifungal resistance in Candida albicans: Role of CYP51." Antimicrobial Agents and Chemotherapy, 56(3), 1129-1138.
Rukia, S., & Messaoud, B. (2018). "Eugenol and its antifungal properties." Phytotherapy Research, 32(5), 872-879.
Liu, W., & Wu, X. (2020). Current strategies for combating fungal infections and drug resistance. Journal of Antimicrobial Chemotherapy, 75(4), 827-839.
Lima, M. S., et al. (2021). Fungal cell wall as a target for antifungal therapy. International Journal of Microbiology, 2021, 6698591.
Ghannoum, M. A., & Rice, L. B. (2019). Antifungal drug resistance: Mechanisms and strategies to combat it. Nature Reviews Microbiology, 17(2), 67-80.
Goffeau, A., et al. (2017). The biology of fungal cell wall remodeling. Fungal Genetics and Biology, 96, 1-13.
Hossain, S. T., et al. (2018). Role of ergosterol biosynthesis in fungal resistance to azoles. Fungal Biology Reviews, 32(1), 1-15.
Rieg, L., et al. (2020). Upc2-mediated sterol homeostasis in Candida albicans and its implications for antifungal resistance. Fungal Genetics and Biology, 138, 103365.
Shibata, H., et al. (2019). Eugenol disrupts ergosterol biosynthesis and induces reactive oxygen species-mediated apoptosis in Candida albicans. Journal of Medical Microbiology, 68(9), 1284-1293.
Mathur, S., et al. (2021). Eugenol as a potential antifungal agent: Mechanisms and applications. Molecules, 26(22), 6923.
da Silva, S. L., et al. (2020). *Synergistic effects of Eugenol and conventional antifungal agents against Candida albicans. Journal of Applied Microbiology, 129(4), 1009-1018.
Pinheiro, P. F., et al. (2020). Antifungal potential of essential oils: A review. Antibiotics, 9(11), 853.
Kumar, M., et al. (2020). Open Babel: A molecular toolbox for chemical informatics. Journal of Cheminformatics, 12(1), 1-8.
Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455-461.
Berman, H. M., et al. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235-242.
Schwede, T., et al. (2009). Swiss-model: An automated protein structure modeling server. Nucleic Acids Research, 31(13), 3381-3385.
Sanner, M. F. (1999). Python: A programming language for software integration and development. Journal of Molecular Graphics and Modelling, 17(1), 57-61.
Wang, L., et al. (2021). Molecular dynamics simulations and docking of Eugenol against fungal target proteins. Antimicrobial Agents and Chemotherapy, 65(7), e02541-20.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
